Navigation Links
Anti-Obesity Groups Criticize Response of Medical Professionals

Medical Professionals’ comments on banning sugary drinks from schools have met with criticism from anti-obesity lobby groups//.

Health Minister Pete Hodgson’s idea to make all schools to be soft drink-free by 2008 to help fight the obesity epidemic has been described as "misguided and based on weak evidence" by Associate Professor Wayne Cutfield and Dr Paul Hofman, diabetes physicians at Starship and Auckland University.

Professor Cutfield described the data linking obesity with fizzy drinks as "too tenuous". He said, ‘If we are going to introduce social legislation, it's got to be based on science and not just common sense because these are major intrusions into people's lives.’

The Agencies for Nutrition Action (ANA) which had advocated the scheme today expressed disappointment with the comments.

According to Dr Rachael Taylor, senior lecturer with the Department of Human Nutrition, University of Otago, there was "no magic bullet" in terms of what contributed to obesity.

"We are never going to cure obesity at a population level from a single dietary change."

She however asserted the fact that beverages were the single largest source of sucrose (sugar) in New Zealand children's diets and contained no useful nutrients. "I don't think anyone expects removing soft drinks from schools will cure obesity but it will create a more healthy environment to match that which is taught in the curriculum."

It has been estimated that about one in 10 children and one in five adults are obese and the extra weight that New Zealanders have been piling on is only burdening the already-overloaded health system.

In addition disorders like heart disease, stroke and type-2 diabetes have been linked to obesity.Plans for spending extra $76 million to fight obesity has already been proposed by the government.

Groups such as the Obesity Action Coalition have called for the ban of high-sugar and
'"/>




Page: 1 2

Related medicine news :

1. Serotonin the Answer for Anti-Obesity Treatment
2. Anti-Obesity Vaccine Successful In Rats
3. Robert Wood Johnson Foundation Pledges $500M To Fund Anti-Obesity Programs
4. Yogic Moments: Age Old Yoga, Benefits All Age Groups
5. Plastic Surgery Is Primetime among Ethnic Groups
6. Study Finds Online Support Groups Emotionally Benefit Women Suffering From
7. Specialist Services Can Help Ethnic Groups To Tackle Alcohol Misuse
8. Distinct Support Services Needed, To Resurrect Ethnic Groups from Alcohol Abuse
9. NGOs and Various Groups Come Together To Address the Issues on AIDS
10. Hospitals Appeal to Citizen Groups to Rush Doctors, Paramedicals
11. Corporate Groups To Participate In Jharkhand Health Care Scheme
Post Your Comments:
(Date:5/16/2008)...sents Urban Health Institute with 10,000 Sensual O...rg at Playboy Mansion Fundraiser, LOS ANGELES, Ma...ip-hop,and R & B artist J Kwon known best for his ...ll be presenting the Urban Health Institute (UHI) ... over $50,000. The donation is,being made to promo...
(Date:5/16/2008)...docs determine who would benefit most from chemo a... 16 (HealthDay News) -- A panel of 15 genes may he...mall cell lung cancer will experience a recurrence...y, a new study shows. , By extension, the same... less aggressive forms of the cancer who would be ...
(Date:5/16/2008)...TON, May 16 /PRNewswire-USNewswire/ -- As tropical...e Irrawaddy delta, survivors of,Cyclone Nargis are... Many,survivors still need assistance, as exposure... an increasingly dire situation., "The people liv...,recover from this disaster and get back on their ...
(Date:5/16/2008)...h Funding Per Death Drops More in 2007, WASHINGTO...ncer causes,one in three cancer deaths, the Nation... its $4.8 billion budget in lung cancer research i...Lung Cancer Alliance (LCA) today., The two other ...programs -- Centers for Disease Control and Preven...
Breaking Medicine News(10 mins):Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2
...dy and you are on a dieting course, there might be...searchers. Nutrition scientists from// Arizona Sta...in the body has a direct relation with the lower b...min C in the blood stream, it could cause increase...
...the risk of obesity, say scientists. Researcher Vi...ice in children’s diet and body mass index (BMI) o...nclusion. // According to foodconsumer.org, he f...cantly lower z-scores for body mass index for thei...
...s been found that children who have the habit of w...han if they don't watch. // And it has also been f... of watching TV during lunchtime, ate comparativel...ows. Dr. Lori Francis, assistant professor of biob...
... health emergencies like predicting about the deve...cientists have devised a simulator, which could ma...bird flu pandemic based on today's environment of ...m of scientists from Los Alamos National Laborator...
Other Medicine News:Health News:Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist! 2Health News:Viewing TV During Lunch Affects Children's Food Intake 2Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 2Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 3Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 4
(Date:5/16/2008)...DGEWATER, N.J., May 16 /- Data from t... mean baseline hemoglobin (Hb) levels,and the rate...fect of,restrictions on reimbursement for erythrop...nts on the nation,s blood supply, will be presente...CO) Annual Meeting later this,month. The meeting w...
(Date:5/16/2008)...,s Technology Enables First-Ever PEGylation of a S...Therapeutic Activity, SAN CARLOS, Calif., May 16 ...daq: NKTR ) announced initial results today from .... The data shows significant,anti-tumor activity i...,also demonstrates that Nektar,s small molecule PE...
(Date:5/16/2008)...le Molecule with Dual Mechanism May Offer Novel Ap...Management, NEW ORLEANS, May 16 /PRNewswire-First... in the discovery and development of novel small,m...0, its first-in-class,Dual Acting Receptor Antagon... pressure reductions in a Phase 2a study in patien...
(Date:5/15/2008)...DCLIFF LAKE, N.J., May 15 /- Eisai Co...sults from 16 clinical data abstracts about,compou...rtfolio and,preclinical oncology research have bee...ting of the American Society of Clinical Oncology ...e 3, 2008., A wide variety of abstracts on Eisai ...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Angiotech to participate in Lehman Brothers Healthcare Conference 4021 1Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 1Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 2Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 3Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 4Clovis age overkill didnt take out Californias flightless sea duck 2530 1Clovis age overkill didnt take out Californias flightless sea duck 2530 2USP Announces Revised Glycerin Monograph 4019 1USP Announces Revised Glycerin Monograph 4019 2USP Announces Revised Glycerin Monograph 4019 3
The NOW® Malaria Test is a field or laboratory test for the differential diagnosis of a Malaria infection. It is intended for the detection of circulating Plasmodium falciparum (P.f.) antigen
...re Monitor (PCM) and Central Station provide an ex...nds the cardiac cath or electrophysiology lab to h...or EP procedures, providing both physiomonitoring ...either standalone or on its own network. Witts Cen...
For the critical care environment, telemetry, emergency room and other monitoring areas.
DS 7600 Central Station
Medicine Products: